By 2025, studies confirm EBV’s presence in MS CNS tissue (e.g., in B cells, astrocytes, neurons), though debated as a marker of infiltration rather than direct infection.  Coinfections like cytomegalovirus may protect against MS severity, while human herpesvirus 6A (HHV-6A) synergizes with EBV.  A 2024 study linked altered immune responses to EBV with MS development. 
Future directions include clarifying if EBV reactivation drives MS flares or is secondary, identifying dysregulated EBV programs in B cells, and testing EBV-specific therapies.  Vaccine trials targeting EBV proteins (e.g., gp350, EBNA1) are underway to prevent MS, with early-phase studies showing promise.     Antivirals and EBV-targeted T-cell therapies could halt progression, potentially averting most MS cases if EBV is prevented.   Challenges remain, such as ensuring vaccines don’t inadvertently trigger autoimmunity. 

Early Associations (1980s–2010s)
Initial observations in the 1980s noted that nearly all MS patients (over 99%) show evidence of prior EBV infection, compared to 90–95% in the general population.   This seropositivity rate holds even in pediatric MS cases (over 95%), far exceeding healthy controls.  Early studies also linked symptomatic EBV infection (infectious mononucleosis) to a doubled risk of MS, with delayed EBV exposure (e.g., in adolescence rather than childhood) increasing susceptibility due to a more severe immune response.  Antibody levels against EBV proteins, particularly EBNA1, were found to be several times higher in MS patients, rising after disease onset and correlating with risk.  Genetic factors, such as the HLA-DRB115:01 allele, were associated with heightened anti-EBNA1 responses and EBV infectivity, while protective alleles like HLA-A02:01 reduced viral load and MS risk. 

The link between Epstein-Barr virus (EBV) and multiple sclerosis (MS) has been investigated for decades, but research in the 2020s has provided compelling evidence that EBV infection is a primary causal factor in the development of MS for most cases. EBV, a common herpesvirus that infects over 90% of the global population and causes infectious mononucleosis (often called “mono”) in some, appears to trigger an autoimmune response in genetically susceptible individuals, leading to the demyelination and inflammation characteristic of MS. While EBV is necessary but not sufficient on its own—requiring interactions with genetic, environmental, and other factors—studies show it dramatically elevates MS risk. Below is a summary of the key research, drawing from epidemiological, mechanistic, and prospective studies.